Leslie Andritsos
University of New Mexico Cancer Center · Ohio State University Comprehensive Cancer Center · Ohio State University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Leslie Andritsos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:41 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03977402 · Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having CancerNew Mexico Cancer Research Alliance · recruiting · Cancer, Cancer Risk · principal investigator
- Ph1NCT01254578 · Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersNational Cancer Institute (NCI) · completed · Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 · principal investigator
- Ph1NCT00466895 · Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.Leslie Andritsos · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT00377104 · Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNational Cancer Institute (NCI) · terminated · B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA016058 · NCI · OHIO STATE UNIVERSITY · PI David M Gosky · fiscal years 2013 to 2026Named on NCT01254578
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01254578, NCT00377104
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:41 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood · 2013704 citationsRCR 17.9
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.J Clin Oncol · 2017435 citationsRCR 12.6
- Ibrutinib treatment improves T cell number and function in CLL patients.J Clin Invest · 2017344 citationsRCR 9.7
- Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.J Clin Oncol · 2009191 citationsRCR 4.3
- 118 citationsRCR 3.4
- 102 citationsRCR 2.3
- 100 citationsRCR 2.8
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.Biol Blood Marrow Transplant · 200983 citationsRCR 2.4
- 64 citationsRCR 3.5
- 61 citationsRCR 1.5